721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study

A compassionate use program of Ipilimumab and nivolumab (IPI-NIVO) was open in Italy from Apr to Oct 2019, enrolling patients (pts) with metastatic renal cell Carcinoma (RCC) with intermediate or poor International Metastatic RCC Database Consortium (IMDC) score. Retrospective analysis of safety and activity of IPI-NIVO administered to pts with metastatic RCC and no prior treatment. IPI was infused at 1 mg/Kg plus Nivolumab 3mg/Kg every three...